Huntington Bancshares stock slips as $1.75 billion note sale adds focus on Cadence deal financing
29 January 2026
1 min read

Huntington Bancshares stock slips as $1.75 billion note sale adds focus on Cadence deal financing

New York, Jan 29, 2026, 11:38 AM EST — Regular session

  • Shares slipped roughly 0.1% in midday trading, following a 2.1% decline on Wednesday
  • On Jan. 28, the bank closed on $1.75 billion worth of senior and subordinated notes.
  • Investors mull over funding decisions and potential integration challenges as the Cadence Bank merger approaches

Huntington Bancshares shares slipped on Thursday after the bank announced a $1.75 billion debt offering, a move that spotlights its balance-sheet strategy ahead of the upcoming Cadence Bank acquisition.

The stock slipped roughly 0.1% to $17.05 in midday trading, following a 2.1% drop on Wednesday. 1

Why it matters now: As rate forecasts shift, regional bank investors are zeroing in on funding costs and capital cushions. Huntington’s note sale comes amid that scrutiny, and only days after the bank filed extra Cadence-related financial exhibits tied to its debt securities offering. 2

Huntington priced $1.0 billion of senior notes with a 4.623% fixed-to-floating rate, maturing in 2032, alongside $750 million of subordinated notes at a 5.605% fixed rate due 2041, according to the bank’s final prospectus supplement. The notes will settle on Jan. 28. 3

The company expects the Cadence merger to close around Feb. 1, 2026, pending any outstanding conditions. 4

Huntington is betting on 2026 as a big growth year, expecting record net interest income (NII) supported by stronger loan demand and wider margins. The bank has also linked part of its forecast to the Cadence deal closing. “Our focus for 2026 remains on driving strong organic growth,” CEO Steve Steinour said in a statement released with last week’s earnings. 5

Traders are keeping a close eye on sector-level reactions to the rate trajectory, as quicker or larger Federal Reserve cuts may squeeze bank margins if loan yields adjust faster than deposit expenses. 6

But risks remain: while issuing long-dated debt boosts liquidity and flexibility, it also risks increasing interest expenses over time. The Cadence integration might trigger one-time costs or operational hiccups that investors will watch closely as the merger wraps up. 3

Investors now await Huntington’s confirmation on the anticipated early-February close of the Cadence deal, alongside any fresh updates on integration schedules or capital strategy linked to the transaction. 4

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Opendoor stock slips as investors parse new SEC filing and mortgage-rate backdrop ahead of earnings
Previous Story

Opendoor stock slips as investors parse new SEC filing and mortgage-rate backdrop ahead of earnings

CoreWeave stock slides as insider sale filing lands, Nvidia-fueled rally cools
Next Story

CoreWeave stock slides as insider sale filing lands, Nvidia-fueled rally cools

Go toTop